Therapeutic Drug Monitoring of Linezolid in Drug-Resistant Tuberculosis Patients: Clinical Factors and Hematological Toxicities
Junjie Cheng,Yuan Yuan,Jinmeng Li,Ruoying Zhang,Xudong Fan,Zhirou Xu,Huirong Lin,Xinjun Cai,Mingfeng Zheng
DOI: https://doi.org/10.2147/idr.s464429
2024-06-21
Infection and Drug Resistance
Abstract:Junjie Cheng, 1, &ast Yuan Yuan, 1, &ast Jinmeng Li, 1 Ruoying Zhang, 1 Xudong Fan, 1 Zhirou Xu, 2 Huirong Lin, 3 Xinjun Cai, 1 Mingfeng Zheng 4 1 Department of Pharmacy, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, People's Republic of China; 2 Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, People's Republic of China; 3 Department of Pharmacy, Taizhou Cancer Hospital, Taizhou, People's Republic of China; 4 Department of Orthopaedics, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Mingfeng Zheng; Xinjun Cai, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, Zhejiang Province, 310003, People's Republic of China, Email ; Purpose: Previous studies have indicated that the development of severe adverse events is associated with linezolid peak concentration (C max ), but the factors affecting linezolid C max and evidences on therapeutic drug monitoring to anticipate toxicity in drug-resistant tuberculosis (DR-TB) patients have not been clarified clearly. This study aimed to explore the factors influencing linezolid C max and investigate the association between linezolid concentration and hematological toxicity. Patients and Methods: This study included patients with drug-resistant tuberculosis treated with linezolid from January 2022 to September 2023. We analyzed the factors affecting linezolid C max using chi-squared and binary logistic regression. The diagnostic utility of linezolid C max in predicting hematological toxicity was evaluated using receiver operating characteristic (ROC) analysis. Results: A total of 76 patients were enrolled in the study. 63.20% met the standard rates for linezolid C max . Age (P=0.036), weight (P=0.0016), and creatinine clearance (P=0.0223) significantly correlated with the C max . Hematological toxicity was observed in 46.05% (35/76) of patients, characterized by thrombocytopenia (31.58%, 24/76), anemia (6.58%, 5/76), and leukopenia (21.05%, 16/76). ROC curve analysis confirmed the predictive value of linezolid C max for thrombocytopenia with an area under curve of 0.728. Conclusion: Suboptimal linezolid C max was prevalent among patients with DR-TB, with age, weight, and renal function emerging as influential factors. Elevated linezolid C max increases the risk of thrombocytopenia. Meticulous monitoring of linezolid C max is imperative during anti-DR-TB therapy to tailor treatment and mitigate hematological toxicity. Keywords: linezolid, therapeutic drug monitoring, influencing factors, hematological toxicity Tuberculosis (TB) is a significant contributor to morbidity and mortality on a global scale, serving as a primary etiological factor and prominent cause of death. Although the WHO Global Tuberculosis Report 2022 provides a cumulative reduction in the tuberculosis incidence rate from 2015 to 2021, the prevalence of drug-resistant TB (DR-TB) has escalated. There is a disparity between the identification and management of DR-TB, and the rate of successful treatment stands at a mere 60%. 1 Linezolid is the first oxazolidinone antibacterial agent that has strong anti-mycobacterial effects by binding to the 50S subunit of Mycobacterium tuberculosis ribosomes, inhibiting the connection of mRNA and ribosomes, and preventing the formation of the 70S initiation complex, thus blocking bacterial protein synthesis in the early stage of translation. 2 Linezolid is recommended as a first-line component of conventional regimens in patients with multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) and those with additional resistance to fluoroquinolones (pre-XDR-TB), according to WHO guidelines. However, linezolid exhibits nonlinear pharmacokinetics with large interindividual variabilities. 3,4 Substandard plasma linezolid concentrations can lead to bacterial drug resistance, disease relapse, and treatment failure. 5 Findings from in vitro testing and molecular testing have indicated that 4.5–5.6% patients with MDR-TB in China exhibited linezolid resistance in 2022, which is the highest rate of linezolid resistance in the world. 6,7 Approximately 41% of patients were found to have inadequate serum levels of linezolid in the treatment of Gram-positive bacterial infections, and the factors that contribute -Abstract Truncated-
pharmacology & pharmacy,infectious diseases